NCT04877106View on ClinicalTrials.gov

Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 7, 2018

Primary Completion Date

May 20, 2018

Study Completion Date

July 31, 2018

Conditions
Healthy Subjects
Interventions
DRUG

Sitagliptin Phosphate/metformin Hydrochloride Tablets(JANUMET®,50mg/850mg)

The subjects randomly received single oral administration of Sitagliptin Phosphate/metformin Hydrochloride Tablets (JANUMET®, 50mg/850mg)

DRUG

Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)

The subjects randomly received single oral administration of Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)

Trial Locations (1)

266003

Phase I Clinical Research Center, Qingdao

All Listed Sponsors
lead

The Affiliated Hospital of Qingdao University

OTHER

NCT04877106 - Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects | Biotech Hunter | Biotech Hunter